VTGN · Vistagen Therapeutics, Inc. · Financials
$0.24
0.00 (-0.84%)
At close · Sep 11
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, we had cash, cash equivalents, and marketable securities of approximately $31.7 million. As of August 14, 2026, the issuance date of the condensed consolidated financial statements in this Quarterly Report as of and for the three months ended June 30, 2026, there is uncertainty about whether our combined cash, cash equivalents, and marketable securities will be sufficient to fund operations beyond twelve months from the issuance date of the condensed consolidated financial statements in this Report and therefore we concluded that substantial doubt exists about our ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$10.52M
Shares
44.38M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$1.27M
+161.1%
FY2026
Net Income
-$69.69M
-35.5%
FY2026
Operating Margin
-5683.69%
+5833.4pp
FY2026
Diluted EPS
-$1.83
-9.6%
FY2026
Operating Cash Flow
-$66.44M
-57.8%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 | FY2004 | FY2003 | FY2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.5M | $1.27M | $486K | $1.06M | -$227K | $1.11M | $1.09M | $0 | — | $0 | $1.25M | $0 | — | — | $200.4K | $1.34M | $2.07M | — | — | — | — | — | — | — | — | — | |
| $1.84M | — | — | — | $26.2K | $19.9K | $1600 | $30.1K | -$8000 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $54.2M | $54.97M | $39.38M | $20.02M | $44.38M | $35.41M | $11.93M | $13.37M | $17.1M | $7.76M | $5.2M | $3.93M | $2.43M | $2.48M | $3.43M | $5.39M | $3.68M | — | — | — | — | — | — | — | — | — | |
| $17.97M | $18.42M | $17.08M | $14.06M | $14.66M | $13.48M | $7.1M | $7.43M | $7.46M | $6.44M | $6.29M | $13.92M | $4.34M | $2.55M | $3.56M | $5M | $4.96M | — | — | — | — | — | — | — | — | — | |
| $211K | $199K | $150K | $127K | $130K | $153.5K | $117.6K | $103.1K | $91.2K | $80.7K | $54.9K | $53.5K | $59.1K | $54.6K | $33.8K | $45.6K | $45.3K | — | — | — | — | — | — | — | — | — | |
| $72.17M | $73.4M | $56.46M | $34.09M | $59.04M | $48.89M | $19.02M | $20.8M | $24.56M | $14.2M | $11.5M | $17.85M | $6.78M | $5.03M | $6.99M | $10.39M | $8.64M | — | — | — | — | — | — | — | — | — | |
| -$69.67M | -$72.13M | -$55.97M | -$33.02M | -$59.27M | -$47.78M | -$17.93M | -$20.8M | -$24.56M | -$14.2M | -$10.25M | -$17.85M | -$6.78M | -$5.03M | -$6.79M | -$9.04M | -$6.56M | — | — | — | — | — | — | — | — | — | |
| — | -5683.69% | -11517.08% | -3103.48% | — | -4308.29% | -1646.06% | — | — | — | -819.88% | — | — | — | -3389.77% | -673.77% | -316.99% | — | — | — | — | — | — | — | — | — | |
| -$69.46M | -$71.93M | -$55.82M | -$32.89M | -$59.14M | -$47.63M | -$17.82M | -$20.7M | -$24.47M | -$14.12M | -$10.19M | -$17.8M | -$6.72M | -$4.97M | -$6.76M | -$9M | -$6.52M | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | $8000 | $8900 | $4600 | $770.8K | $4.55M | $1.5M | -$920.7K | -$1.89M | $3.12M | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | $0 | $600 | — | — | — | $0 | -$2300 | -$135K | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$67.61M | -$69.68M | -$51.41M | -$29.36M | -$59.24M | -$47.76M | -$17.93M | -$20.77M | -$24.59M | -$14.34M | -$10.25M | -$47.22M | -$13.88M | -$2.97M | -$12.88M | -$12.21M | -$9.48M | — | — | — | — | — | — | — | — | — | |
| $7000 | $7000 | $7000 | $4000 | $6000 | $3400 | $2600 | $2600 | $2600 | $2400 | $2400 | $2300 | $2400 | $2700 | $3700 | $1600 | $1600 | — | — | — | — | — | — | — | — | — | |
| -$67.62M | -$69.69M | -$51.42M | -$29.36M | -$59.25M | -$47.76M | -$17.93M | -$20.77M | -$24.59M | -$14.35M | -$10.26M | -$47.22M | -$13.89M | -$2.97M | -$12.89M | -$12.21M | -$9.48M | -$4.12M | -$4.7M | -$5.45M | -$2M | -$1.77M | -$1.08M | -$8.76M | -$502.6K | -$2.11M | |
| — | -5491.33% | -10579.84% | -2759.59% | — | -4306.8% | -1646.09% | — | — | — | -820.44% | — | — | — | -6430.49% | -909.66% | -457.86% | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | -$59.25M | -$48.71M | -$42.32M | -$22.04M | -$25.73M | -$15.58M | -$11.62M | -$51.42M | -$13.89M | -$2.97M | $185.7K | — | — | — | — | — | — | — | — | — | — | — | |
| -$67.63M | -$69.69M | -$51.41M | -$29.36M | -$59.25M | — | — | — | — | — | — | — | — | -$2.97M | -$12.89M | — | — | — | — | — | — | — | — | — | — | — | |
| USD/shares | -$1.66 | -$1.83 | -$1.67 | -$1.52 | -$8.51 | -$7.38 | -$14.70 | — | — | — | — | -$872.40 | -$315.90 | -$81.00 | $0.30 | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | -$1.66 | -$1.83 | -$1.67 | -$1.52 | -$8.51 | — | — | — | — | — | — | -$872.40 | -$318.30 | -$114.30 | -$0.60 | -$24.90 | -$54.30 | — | — | — | — | — | — | — | — | — |
| shares | — | 38.07M | 30.88M | 19.35M | 6.96M | 6.6M | 2.87M | 1.46M | 952.08K | 463K | 251.05K | 58.93K | 43.96K | 36.62K | 694.66K | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 38.07M | 30.88M | 19.35M | 6.96M | — | 2.87M | 1.46M | 952.08K | 463K | 251.05K | 58.93K | 43.96K | 36.64K | 694.66K | 491.22K | 174.7K | — | — | — | — | — | — | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Showing the latest 26 of 27 periods — chart a line item for full history.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.92×
EV/EBIT
—
P/E (TTM)
—
Peer median 3.06×
Peer medians compare against the 212 similar-size Biotechnology companies (of 536 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2023 | FY2022 |
|---|---|---|
| License | -$227,000 | $1,109,000 |
Key facts
CIK
1411685
CUSIP
92840H400
13F (30d)
22 filings
22 filers
Visit website
Investor relations